Health Canada vs FDA: approval paths

When a new drug reaches regulators, it does not always travel the same road. Both Health Canada and the US Food and Drug Administration operate a set of expedited pathways alongside their standard reviews. A June 2026 cross-sectional study by Joel Lexchin in the Journal of General Internal Medicine^[1] compared how the two agencies actually use those pathways. The question matters because the pace of regulatory review shapes when patients in Canada and the United States gain access to approved treatments, including GLP-1 receptor agonists like semaglutide.

What expedited pathways exist at each agency

The FDA runs four distinct programmes that can accelerate the path from submission to approval. Fast Track designation is awarded early in development when a drug targets a serious condition with unmet need. Breakthrough Therapy is a more intensive designation that also involves collaborative FDA guidance. Priority Review cuts the standard 12-month review clock to six months. Accelerated Approval allows conditional approval on a surrogate endpoint, with a post-market confirmatory trial required.

Health Canada's toolkit is narrower. Its main expedited instruments are Priority Review, which shortens the target review time from 300 days to 180 days, and Notice of Compliance with conditions (NOC/c), which is structurally similar to the FDA's Accelerated Approval: the drug gains market entry on the basis of promising but incomplete evidence, and the manufacturer must provide confirmatory data^[2]. Canada does not have direct equivalents of the FDA's Fast Track or Breakthrough Therapy designations.

What earlier research found about pathway use

A 2018 cross-sectional analysis by Lexchin covering Health Canada approvals from 1995 to 2016 found that 70.3% of 623 approved drugs went through the standard pathway and 29.7% went through an expedited route^[3]. That latter group looked large, but the study found poor alignment between expedited status and genuine therapeutic innovation. The kappa coefficient measuring agreement between Health Canada's expedited classifications and independent therapeutic assessments was just 0.276, rated as 'fair'. In other words, most of the drugs that received a fast lane were not therapeutically novel.

A 2021 study examining both agencies' responses to failed confirmatory trials for oncology drugs found a different pattern. When surrogate-endpoint approvals were not validated by post-market evidence, the FDA made regulatory decisions earlier than Health Canada. The two agencies reached similar final conclusions in most cases, but the speed gap was meaningful for the patients whose treatments were affected.

The 2026 cross-sectional study

The Lexchin 2026 JGIM letter^[1] extends this line of work to a direct cross-sectional comparison of pathway usage at both agencies. Published online on 29 June 2026, the study applies a cross-sectional design to characterise how frequently each agency reaches for its expedited tools, and whether that frequency has shifted over time. The conflict of interest statement notes involvement in semaglutide-related matters, placing the paper in the context of the current GLP-1 regulatory debate. The letter format means the study is a focused report rather than a full-length article.

The broader regulatory question is whether expedited pathways are working as intended. A 2026 systematic review and meta-analysis found that priority review drugs were significantly more likely to be of high added clinical value (odds ratio 5.39; 95% CI 3.44 to 8.44) compared to standard-review drugs^[4]. Conditional approval drugs, however, were no more likely to be of high added clinical value, but carried a higher rate of post-approval safety concerns (risk ratio 1.89).

What this means for GLP-1 patients in Canada

For patients waiting on access to treatments like semaglutide, the regulatory pathway question is not abstract. Canada and the United States have approved the same GLP-1 drugs, but not always on the same timeline or under the same conditions. Health Canada approved semaglutide (Ozempic) for type 2 diabetes in 2018 and the higher-dose formulation (Wegovy) for chronic weight management. Public drug plan reimbursement, which is handled province by province rather than federally, adds another layer of delay that the US system does not have in the same form.

The implication of comparative pathway research is not that one agency is better than the other. The FDA's larger toolkit allows faster conditional entry but also produces more post-market safety withdrawals. Health Canada's more conservative structure reduces some early-access risk but can extend the wait for patients in serious-need categories. The gap between what is approved and what is reimbursed is a separate and often longer delay that pathway design alone cannot close. For per-country reimbursement detail, see Canada regulation and US regulation.

Limitations of the cross-sectional design

Cross-sectional studies capture a snapshot rather than a trend. They can describe how often a pathway was used across a period, but they do not establish whether the pathway choice caused a better or worse outcome for patients. The Lexchin 2026 paper is a letter, which means its findings are condensed and have not undergone full peer review of a longer methodology section. Readers looking for causal claims about pathway efficiency should consult the 2026 systematic review^[4] and the earlier longitudinal Health Canada data alongside it. For the GLP-1 class specifically, see our coverage of semaglutide for the approved indications and timelines that result from these agency processes.